▲ Peaking
Business
🔮 holds
Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors
Q32 Bio's stock surged 60% following positive phase 2 trial results for Bempikibart, a potential competitor to JAK inhibitors in treating alopecia areata.